Effects of VRX496-T on viral load and CD4 counts. (A) Average CD4 counts in patients after infusion and before ATI, with 252 plotted separately as an outlier. (B) CD4 counts in patients after resuming ARVafter ATI. No difference was observed between patients never on ATI and those who resumed ARV after ATI (P = .2345). (C) Virus recrudescence after ATI. (D) Viral set point analysis. Shown are the average of historic set point readings (♢) and the after ATI viral load readings averaged at week 10 and 14 after ATI (■). Patient 252 ultimately did have a measurable viral load, but it was undetectable at weeks 10 and 14 when the post-ATI set point was assessed.